QS100

QS100 is an investigational **cell-based regenerative therapy** being developed by Qrons for **penetrating traumatic brain injury**. Public company and product descriptions characterize it as an **injury-specific, 3D-printable, implantable mesenchymal stem cell synthetic hydrogel** that combines proprietary modified mesenchymal stem cells with a synthetic hydrogel or scaffold material intended to repair neuronal damage and improve recovery after severe brain trauma. The product appears to be at a **preclinical or early development** stage, and its precise molecular mechanism, manufacturing details, and definitive clinical formulation have not been fully disclosed in authoritative public sources.